BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stark T, Ruda-kucerova J, Iannotti FA, D'addario C, Di Marco R, Pekarik V, Drazanova E, Piscitelli F, Bari M, Babinska Z, Giurdanella G, Di Bartolomeo M, Salomone S, Sulcova A, Maccarrone M, Wotjak CT, Starcuk Z, Drago F, Mechoulam R, Di Marzo V, Micale V. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology 2019;146:212-21. [DOI: 10.1016/j.neuropharm.2018.11.035] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Rincón-cortés M, Grace AA. Adult stress exposure blunts dopamine system hyperresponsivity in a neurodevelopmental rodent model of schizophrenia. Schizophr 2022;8:30. [DOI: 10.1038/s41537-022-00235-x] [Reference Citation Analysis]
2 Micale V, Di Bartolomeo M, Di Martino S, Stark T, Dell'osso B, Drago F, D'addario C. Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets. Pharmacology & Therapeutics 2022. [DOI: 10.1016/j.pharmthera.2022.108279] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Hazani R, Lavidor M, Weller A. Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis. Schizophr Bull 2022:sbac093. [PMID: 35925025 DOI: 10.1093/schbul/sbac093] [Reference Citation Analysis]
4 Ahmed M, Best LM, Pereira CF, Boileau I, Kloiber S. Effects of endocannabinoid system modulation on social behaviour: A systematic review of animal studies. Neurosci Biobehav Rev 2022;138:104680. [PMID: 35513169 DOI: 10.1016/j.neubiorev.2022.104680] [Reference Citation Analysis]
5 Kibret BG, Ishiguro H, Horiuchi Y, Onaivi ES. New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. Int J Mol Sci 2022;23:975. [PMID: 35055161 DOI: 10.3390/ijms23020975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
6 Stark T, Iannotti FA, Di Martino S, Di Bartolomeo M, Ruda-kucerova J, Piscitelli F, Wotjak CT, D’addario C, Drago F, Di Marzo V, Micale V. Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. Biomolecules 2022;12:108. [DOI: 10.3390/biom12010108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Henson JD, Vitetta L, Quezada M, Hall S. Enhancing Endocannabinoid Control of Stress with Cannabidiol. J Clin Med 2021;10:5852. [PMID: 34945148 DOI: 10.3390/jcm10245852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Weeks JJ, Grace AA, Sved AF. Nicotine Administration Normalizes Behavioral and Neurophysiological Perturbations in the MAM Rodent Model of Schizophrenia. Int J Neuropsychopharmacol 2021;24:979-87. [PMID: 34622270 DOI: 10.1093/ijnp/pyab064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Raffaele M, Kovacovicova K, Biagini T, Lo Re O, Frohlich J, Giallongo S, Nhan JD, Giannone AG, Cabibi D, Ivanov M, Tonchev AB, Mistrik M, Lacey M, Dzubak P, Gurska S, Hajduch M, Bartek J, Mazza T, Micale V, Curran SP, Vinciguerra M. Nociceptin/orphanin FQ opioid receptor (NOP) selective ligand MCOPPB links anxiolytic and senolytic effects. Geroscience 2021. [PMID: 34820764 DOI: 10.1007/s11357-021-00487-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
10 de Melo Reis RA, Isaac AR, Freitas HR, de Almeida MM, Schuck PF, Ferreira GC, Andrade-da-Costa BLDS, Trevenzoli IH. Quality of Life and a Surveillant Endocannabinoid System. Front Neurosci 2021;15:747229. [PMID: 34776851 DOI: 10.3389/fnins.2021.747229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
11 Helcman M, Šmejkal K. Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases. Phytochem Rev. [DOI: 10.1007/s11101-021-09777-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Stark T, Di Martino S, Drago F, Wotjak CT, Micale V. Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacol Res 2021;174:105938. [PMID: 34655773 DOI: 10.1016/j.phrs.2021.105938] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
13 Brancato A, Castelli V, Lavanco G, Tringali G, Micale V, Kuchar M, D'Amico C, Pizzolanti G, Feo S, Cannizzaro C. Binge-like Alcohol Exposure in Adolescence: Behavioural, Neuroendocrine and Molecular Evidence of Abnormal Neuroplasticity… and Return. Biomedicines 2021;9:1161. [PMID: 34572345 DOI: 10.3390/biomedicines9091161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
14 Chiodi V, Domenici MR, Biagini T, De Simone R, Tartaglione AM, Di Rosa M, Lo Re O, Mazza T, Micale V, Vinciguerra M. Systemic depletion of histone macroH2A1.1 boosts hippocampal synaptic plasticity and social behavior in mice. FASEB J 2021;35:e21793. [PMID: 34320234 DOI: 10.1096/fj.202100569R] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Hoffman KL. From the Clinic to the Laboratory, and Back Again: Investigations on Cannabinoids and Endocannabinoid System Modulators for Treating Schizophrenia. Front Psychiatry 2021;12:682611. [PMID: 34290632 DOI: 10.3389/fpsyt.2021.682611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Kwan Cheung KA, Mitchell MD, Heussler HS. Cannabidiol and Neurodevelopmental Disorders in Children. Front Psychiatry 2021;12:643442. [PMID: 34093265 DOI: 10.3389/fpsyt.2021.643442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
17 Pedrazzi JFC, Sales AJ, Guimarães FS, Joca SRL, Crippa JAS, Del Bel E. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum. Prog Neuropsychopharmacol Biol Psychiatry 2021;111:110352. [PMID: 34015384 DOI: 10.1016/j.pnpbp.2021.110352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
18 Ferber SG, Hazani R, Shoval G, Weller A. Targeting the Endocannabinoid System in Borderline Personality Disorder: Corticolimbic and Hypothalamic Perspectives. Curr Neuropharmacol 2021;19:360-71. [PMID: 32351183 DOI: 10.2174/1570159X18666200429234430] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
19 Graczyk M, Łukowicz M, Dzierzanowski T. Prospects for the Use of Cannabinoids in Psychiatric Disorders. Front Psychiatry 2021;12:620073. [PMID: 33776815 DOI: 10.3389/fpsyt.2021.620073] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
20 Loss CM, Teodoro L, Rodrigues GD, Moreira LR, Peres FF, Zuardi AW, Crippa JA, Hallak JEC, Abílio VC. Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders? Front Pharmacol 2020;11:635763. [PMID: 33613289 DOI: 10.3389/fphar.2020.635763] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Zhang XQ, Xu L, Ling Y, Hu LB, Huang J, Shen HW. Diminished excitatory synaptic transmission correlates with impaired spatial working memory in neurodevelopmental rodent models of schizophrenia. Pharmacol Biochem Behav 2021;202:173103. [PMID: 33444600 DOI: 10.1016/j.pbb.2021.173103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Maćkowiak M. The MAM-E17 neurodevelopmental model of schizophrenia. Diagnosis, Management and Modeling of Neurodevelopmental Disorders 2021. [DOI: 10.1016/b978-0-12-817988-8.00050-6] [Reference Citation Analysis]
23 Di Bartolomeo M, Stark T, Maurel OM, Iannotti FA, Kuchar M, Ruda-Kucerova J, Piscitelli F, Laudani S, Pekarik V, Salomone S, Arosio B, Mechoulam R, Maccarrone M, Drago F, Wotjak CT, Di Marzo V, Vismara M, Dell'Osso B, D'Addario C, Micale V. Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacol Res 2021;164:105357. [PMID: 33285233 DOI: 10.1016/j.phrs.2020.105357] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
24 García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules 2020;10:E1575. [PMID: 33228239 DOI: 10.3390/biom10111575] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 23.5] [Reference Citation Analysis]
25 Kong FC, Ma CL, Zhong MK. Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application. Curr Neuropharmacol 2020;18:153-66. [PMID: 31660836 DOI: 10.2174/1570159X17666191010094849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Kucera J, Horska K, Hruska P, Kuruczova D, Micale V, Ruda-Kucerova J, Bienertova-Vasku J. Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue. Prog Neuropsychopharmacol Biol Psychiatry 2021;108:110165. [PMID: 33152383 DOI: 10.1016/j.pnpbp.2020.110165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Di Marzo V. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
. Dialogues Clin Neurosci 2020;22:259-69. [PMID: 33162769 DOI: 10.31887/DCNS.2020.22.3/vdimarzo] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
28 Horska K, Kotolova H, Karpisek M, Babinska Z, Hammer T, Prochazka J, Stark T, Micale V, Ruda-Kucerova J. Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation. Toxicol Appl Pharmacol 2020;406:115214. [PMID: 32866524 DOI: 10.1016/j.taap.2020.115214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
29 Patel PK, Leathem LD, Currin DL, Karlsgodt KH. Adolescent Neurodevelopment and Vulnerability to Psychosis. Biol Psychiatry 2021;89:184-93. [PMID: 32896384 DOI: 10.1016/j.biopsych.2020.06.028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 12.5] [Reference Citation Analysis]
30 Dunn AL, Michie PT, Hodgson DM, Harms L. Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models. Neurosci Biobehav Rev 2020;116:202-20. [PMID: 32610181 DOI: 10.1016/j.neubiorev.2020.06.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Fellous T, De Maio F, Kalkan H, Carannante B, Boccella S, Petrosino S, Maione S, Di Marzo V, Iannotti FA. Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. Biochemical Pharmacology 2020;175:113859. [DOI: 10.1016/j.bcp.2020.113859] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
32 Stark T, Di Bartolomeo M, Di Marco R, Drazanova E, Platania CBM, Iannotti FA, Ruda-Kucerova J, D'Addario C, Kratka L, Pekarik V, Piscitelli F, Babinska Z, Fedotova J, Giurdanella G, Salomone S, Sulcova A, Bucolo C, Wotjak CT, Starcuk Z Jr, Drago F, Mechoulam R, Di Marzo V, Micale V. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochem Pharmacol 2020;177:114004. [PMID: 32360362 DOI: 10.1016/j.bcp.2020.114004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
33 Krebs MO, Demars F, Frajerman A, Kebir O, Jay T. [Neurodevelopment and cannabis]. Bull Acad Natl Med 2020;204:561-9. [PMID: 32308209 DOI: 10.1016/j.banm.2020.04.002] [Reference Citation Analysis]
34 Rodrigues da Silva N, Gomes FV, Sonego AB, Silva NRD, Guimarães FS. Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. Pharmacol Res 2020;156:104749. [PMID: 32151683 DOI: 10.1016/j.phrs.2020.104749] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
35 Pauli CS, Conroy M, Vanden Heuvel BD, Park SH. Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects. Front Pharmacol 2020;11:63. [PMID: 32161538 DOI: 10.3389/fphar.2020.00063] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
36 Fernández-Ruiz J, Galve-Roperh I, Sagredo O, Guzmán M. Possible therapeutic applications of cannabis in the neuropsychopharmacology field. Eur Neuropsychopharmacol 2020;36:217-34. [PMID: 32057592 DOI: 10.1016/j.euroneuro.2020.01.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
37 Singer L, Tokish H, Park F, Campisi C, Milanaik RL. The cannabidiol conundrum: potential benefits and risks of cannabidiol products for children. Current Opinion in Pediatrics 2020;32:198-205. [DOI: 10.1097/mop.0000000000000861] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Stark T, Iannotti F, Piscitelli F, Ruda-kucerova J, Drago F, Sulcova A, Di Marzo V, Micale V. P.705 Neonatal CB1 receptor blockade differentially affects behavioural responses in normal and prenatally MAM exposed rats. European Neuropsychopharmacology 2019;29:S476-S477. [DOI: 10.1016/j.euroneuro.2019.09.747] [Reference Citation Analysis]
39 Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol 2019;9:2045125319881916. [PMID: 31741731 DOI: 10.1177/2045125319881916] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 16.0] [Reference Citation Analysis]
40 Osborne AL, Solowij N, Babic I, Lum JS, Newell KA, Huang XF, Weston-Green K. Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2019;95:109666. [PMID: 31202911 DOI: 10.1016/j.pnpbp.2019.109666] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
41 Schleicher EM, Ott FW, Müller M, Silcher B, Sichler ME, Löw MJ, Wagner JM, Bouter Y. Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice. Front Behav Neurosci 2019;13:94. [PMID: 31133833 DOI: 10.3389/fnbeh.2019.00094] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
42 Drazanova E, Ruda-Kucerova J, Kratka L, Stark T, Kuchar M, Maryska M, Drago F, Starcuk Z Jr, Micale V. Different effects of prenatal MAM vs. perinatal THC exposure on regional cerebral blood perfusion detected by Arterial Spin Labelling MRI in rats. Sci Rep 2019;9:6062. [PMID: 30988364 DOI: 10.1038/s41598-019-42532-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]